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Abstract
Background:  Influenza virus infection or vaccination evokes an antibody response to viral
hemagglutinin (HA) and neuraminidase (NA) surface glycoproteins, which results in immunity
against influenza A viruses of the same HA and NA subtype. A heterosubtypic immune response
that offers some protection against different influenza A subtypes has been suggested from
epidemiologic studies in human influenza outbreaks, and has been induced in experimental animal
models. Original studies of such cross-protection showed that cytotoxic T lymphocytes (CTL)
protect H3N2-immune mice from a lethal H1N1 infection. More recent studies in mice
demonstrate that antibodies also contribute to heterosubtypic immunity (HSI). We previously
demonstrated that HSI in cotton rats (Sigmodon hispidus) is characterized by protection of H3N2-
immune animals from influenza H1N1-induced increase in respiratory rate (tachypnea).
Alternatively, H1N1-immune animals are protected from H3N2-induced tachypnea. The
experiments described in this report were designed to elucidate the immune mechanism that
prevents this very early sign of disease.
Results: Our results show that cotton rats provided with H1N1-immune serum prior to challenge
with an H3N2 virus were protected from influenza-associated tachypnea, with the degree of
protection correlating with the antibody titer transferred. Immunization with an inactivated
preparation of virus delivered intramuscularly also provided some protection suggesting that CTL
and/or mucosal antibody responses are not required for protection. Antibodies specific for
conserved epitopes present on the virus exterior are likely to facilitate this protection since
prophylactic treatment of cotton rats with anti-M2e (the extracellular domain of M2) but not anti-
nucleoprotein (NP) reduced virus-induced tachypnea.
Conclusion: In the cotton rat model of heterosubtypic immunity, humoral immunity plays a role
in protecting animals from influenza-induced tachypea. Partial protection against respiratory
disease caused by different influenza A subtypes can be attained with either live virus administered
intranasally or inactivated virus delivered intramuscularly suggesting that either vaccine regimen
may provide some protection against potential pandemic outbreaks in humans.
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Background
Influenza A remains a major burden on mankind with
annual epidemics of disease and continued potential for
devastating pandemics such as that seen in 1918. Neutral-
izing antibodies that are specific for viral hemagglutinin
(HA) and neuraminidase (NA) are induced following
immunization with inactivated influenza vaccines and
correlate with protective immunity against influenza
strains of the same subtype. These specific antibodies do
not offer protection against viruses that have a different
HA and NA subtype, as noted in the vaccine failure in
1947 when an H1N1 virus emerged that was serologically
distinct from the 1943 H1N1 strain used in the vaccine
[1]. A more recent example of limited reactivity with a
drifted influenza strain occurred in the 2003–2004 season
when the vaccine contained an H3N2 virus that was anti-
genically distinct from newly circulating A/Fujian strain
[2]. During this particular season it appeared that the live
attenuated vaccine provided individuals with some pro-
tection against drifted strains of influenza [3], suggesting
that a replicating virus administered intranasally is more
likely to induce more broadly acting antibodies or cross-
reactive cellular immune mechanisms that can act at the
site of infection.
While immunity to influenza is primarily type and sub-
type-specific, epidemiologic evidence suggests that heter-
osubtypic immunity can be induced in man [4].
Retrospective studies that show a lower incidence of
H2N2 influenza disease in persons previously infected
with an H1N1 virus also support this idea [5]. However,
the immune responses that correlate with protection of
humans against infection with an influenza virus that is of
a different subtype have not been characterized. Studies in
influenza-infected mice suggest that multiple mecha-
nisms may contribute to this type of protection. Tradition-
ally, cell mediated immune mechanisms against
conserved antigen targets have been considered responsi-
ble for a cross-protective immune response [6,7]. In con-
trast, more recent studies demonstrate a role for antibody
in heterosubtypic immunity in mice [8,9]. These studies
suggest that the magnitude of the immune response as
well as the route of immunization is important in estab-
lishing antibody-mediated cross-protection.
The specificity of antibodies that provide protection
against different influenza A subtypes are likely to be non-
neutralizing, since antibodies that block HA-binding or
inhibit NA activity are generally thought of as subtype-
specific. These could include antibodies that recognize
conserved portions of surface glycoproteins or antigens in
the viral core. Examples of potential epitopes include a
conserved peptide at the cleavage site of the influenza B
HA molecule (this peptide has been used to induce immu-
nity against influenza B strains that are antigenically dis-
tinct [10]) and the conserved extracellular peptide of M2
(M2e). It has been demonstrated that a monoclonal anti-
body with specificity for M2e inhibits influenza replica-
tion in mice [11] and that a M2e vaccine protects against
lethal challenge with both H1N1 and H3N2 influenza A
viruses in mice, and reduces shedding of viruses in ferrets
[12].
We have used the cotton rat (Sigmodon hispidus) to study
influenza pathogenesis and immunity. This unique
model has the distinct advantage of exhibiting increased
respiratory rate (tachypnea) following infection with
influenza, a response that is dependent on virus dose and
immune status. Respiratory rates are easily monitored by
whole body plethysmography, making this a practical
end-point to evaluate protection from influenza-induced
respiratory disease or vaccine efficacy. We previously
established that cotton rats can be used as a model to
study heterosubtypic immunity against influenza A; ani-
mals exposed to one subtype of virus are protected from
respiratory disease upon exposure to a different subtype of
influenza A [13]. This protection is retained when animals
are treated with steroid to inhibit the inflammatory
response, suggesting that heterosubtypic immunity is not
dependent on a recruited cellular response. In this report,
we show that protection against influenza-induced tach-
ypnea is transferred in serum from animals previously
infected with an influenza virus of a different subtype, and
examine the potential specificity of the cross-protective
antibodies, as well as the route of immunization required
to induce heterosubtypic immunity.
Results
Cross-protection is observed following the prophylactic 
transfer of serum from immunized animals to naïve cotton 
rats
Previous studies in our laboratory demonstrated that pro-
tection from respiratory disease was retained in immune
animals after the administration of systemic steroids,
which inhibited the acute inflammatory response follow-
ing challenge with a heterosubtypic virus [14]. These
results suggested that the heterosubtypic immune
response was not mediated by recruited cells, but rather
by local cells at the site of infection or cross-reactive anti-
bodies. To further evaluate whether antibodies play a role
in heterosubtypic immunity, we transferred serum from
H1N1 or H3N2-immune cotton rats into naïve cotton rats
24 hr before intra-nasal (i.n.) challenge with 107 TCID50/
100 g A/Wuhan/95, an H3N2 virus. Respiratory rates (RR)
were measured 1 and 2 days later by whole body plethys-
mography.
The group of animals that received H3N2-immune serum
prior to viral challenge with H3N2 virus was significantly
protected (p < 0.03) from the effects of respiratory diseaseVirology Journal 2008, 5:44 http://www.virologyj.com/content/5/1/44
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compared to the group undergoing primary infection. The
challenge group that was previously infected with the
homotypic H3N2 virus was also protected from virus-
induced tachypnea (p < 0.02). Passive transfer of H1N1-
immune serum into 4 animals resulted in a strong trend
toward protection, but the respiratory rates measured
were not significantly different from the those measured
in non-immune animals (p = 0.06). These results are pre-
sented in Fig. 1 as the mean percent protection from
H3N2-induced tachypnea, with respiratory rates for day 2
post-challenge provided in the figure legend.
Variation in the degree of protection in recipients of
H1N1-immune serum suggested that the i.p. inoculation
of serum may not always transfer an equal amount of anti-
body into the circulation. To assess the quantity of anti-
body transferred in each animal, we measured
hemagglutination inhibition (HAI) titers in the serum of
recipients 12 hr after intraperitoneal (i.p.) transfer of
immune sera. The degree of protection from tachypnea
correlated with the recipient's pre-challenge HAI titer (Fig.
2A), with Spearman's correlation coefficient of -0.71 (p <
0.02). In general, animals with higher HAI titers demon-
strated lower RR than recipients of naïve serum. In subse-
quent passive transfer studies, only animals with an HAI
titer of 40 or greater were considered successful transfer
recipients and an HAI titer ≥ 40 was a prerequisite for
including individual animal results in the data analysis.
Correlation of protection against tachypnea and HAI titer  after passive transfer of heterosubtypic immune sera Figure 2
Correlation of protection against tachypnea and HAI 
titer after passive transfer of heterosubtypic immune 
sera. Respiratory rates (breaths per minute) and serum HAI 
titers are shown for individual animals in A. These animals 
were challenged with A/Wuhan/95 (H3N2) after receipt of 
H1N1-immune sera. The best fit line and 95% confidence 
intervals are displayed in the figure. The Spearman's correla-
tion coefficient was -0.71 (p < 0.02). Percent protection from 
tachypnea for groups of animals that received immune sera 
before H3N2 challenge is shown in B. These groups included 
animals that did not receive serum, or groups that received 
from naïve, H1N1-immune or H3N2-immune animals. The 
mean protection was calculated using results from animals 
that had HAI titer ≥ 40 following serum transfer. Results are 
also shown for control groups that were immune to the 
homotypic or heterosubtypic virus at the time of challenge. 
Percent protection of different groups were compared by 
Mann-Whitney test, with statistical significant differences (p < 
0.05) with the group experiencing primary infection in the 
absence of immune serum marked with a *.
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Transfer of H1N1-immune serum protects recipient cotton  rats against H3N2-induced tachypnea Figure 1
Transfer of H1N1-immune serum protects recipient 
cotton rats against H3N2-induced tachypnea. Mean 
percent protection (± SEM) is shown for animals that 
received H1N1 or H3N2-immune sera and were then chal-
lenged with an H3N2 virus, A/Wuhan/95. The immune sera 
were obtained from cotton rats previously infected with A/
PR/8/34 (H1N1) or A/Wuhan/95 (H3N2). Peak respiratory 
rates were measured on day 2 after challenge and were used 
to calculate the mean percent protection from virus-induced 
tachypnea shown in the figure.
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Data collected 2 days post-infection in one such experi-
ment are displayed in Fig. 2B, showing mean percent pro-
tection calculated from the mean respiratory rates
provided for each animal group in the figure legend. Sta-
tistical analysis showed that the RR of animals receiving
either heterosubtypic (A/PR/8/34)-immune or homolo-
gous (A/Wuhan/95)-immune-serum were significantly
less than naïve animals undergoing primary infection (p <
0.03 and p < 0.01 respectively). Previous studies show that
tachypnea is close to resolution by day 4 post-infection
and therefore respiratory rates were not measured at this
time point. At this late time point, animals did not exhibit
any gross difficulty in breathing, and did not have
increased histopathology, suggesting that there was no
exacerbation of disease. Animals administered non-
immune serum prior to transfer did not differ significantly
from animals undergoing primary disease (p = 0.24).
Neutralizing antibodies in serum of immune cotton rats 
are subtype specific
To evaluate whether antibodies with hemagglutination
inhibition activity contribute to this in vivo cross-protec-
tion, we examined the ability of serum from H1N1-
immune animals (the same pool of serum that had been
used in the transfer study) to inhibit agglutination of red
blood cells by A/Wuhan/95 (H3N2). The pooled serum
had an HAI titer of 640 against A/PR/8/34 but <10 against
A/Wuhan/95 (Table 1). This lack of cross-reactivity is
expected, indicative of a subtype-specific neutralizing
antibody response. To evaluate whether the antibodies
that neutralize virus replication are truly subtype-specific
in this model, we also determined the amount of anti-
body required to inhibit replication of H1N1 or H3N2
viruses in MDCK cells. The tissue-culture neutralizing titer
for H1N1-immune serum in this assay was 1600 against
A/PR/8/34 and <100 against A/Wuhan/95. Because com-
plement component C1q can enhance the activity of anti-
bodies [15], the neutralization assay was also performed
in the presence of complement. Addition of C1q
increased the neutralizing antibody titer to 3200 but did
not change the specificity of the inhibition. A pool of
serum from A/Wuhan/95-immune animals showed simi-
lar subtype specificity, with a titer of 200 against A/
Wuhan/95 that increased to 800 in the presence of com-
plement. Even in the presence of complement, this serum
did not inhibit A/PR/8/34 replication at the lowest dilu-
tion of antibody used (1/100). Antibodies that inhibited
NA activity were also subtype specific; the NA inhibition
(NI) titer of H1N1-immune serum that had been used in
transfer studies was 80 against A/PR/8/34 and no detecta-
ble inhibition was measured against the N2 activity of A/
Wuhan/95. The NI titer of H3N2-immune serum was 320
against A/Wuhan/95 and there was no detectable inhibi-
tion against the NI activity of A/PR/8/34.
Protection from virus-induced tachypnea is achieved by 
prophylactic administration of antibodies specific for viral 
M2 but not viral NP
Antibody with specificity for M2e provides protection
against influenza A replication in mice, and therefore has
the potential to play a role in reducing tachypnea follow-
ing infection of cotton rats. To test whether this is the case,
groups of cotton rats were treated (i.p. inoculation) with
100 μg monoclonal antibody specific for either influenza
nucleoprotein (NP) or M2e 6 hr before infection with A/
Wuhan/95 (107 TCID50/100 g). Four animals were used in
each group. Cotton rats that received anti-M2e, but not
anti-NP prior to challenge were subsequently protected
from tachypnea an (p < 0.04, and p < 0.48, respectively).
These results are shown in Fig. 3.
Heterosubtypic immunity is observed following 
immunization with UV-inactivated virus that is delivered 
intramuscularly, and does not require immunization with 
live virus
Since our cotton rat model of heterosubtypic immunity
was established using live virus to vaccinate cotton rats
i.n., we examined the ability of inactivated virus to protect
animals from virus-induced tachypnea. We also deter-
mined whether mucosal immunization was essential to
Table 1: Subtype-specific antibody responses are evident in sera from A/PR/8/34(H1N1) and A/Wuhan/95(H3N2)-infected animals.
Antibody titer as measured bya
HAI NI Neutralization Neut + C1q
Serum source H1N1 H3N2 H1N1 H3N2 H1N1 H3N2 H1N1 H3N2
Naïve serum <10 <10 0 0 <100 <100 <100 <100
H1N1-immune 640 <10 80 0 1600 <100 3200 <100
H3N2-immune <10 160 0 320 <100 200 <100 800
aStandard hemagglutination inhibition (HAI), neuraminidase inhibition (NI) and neutralization (neut) assays in the absence as well as presence of 
complement factor C1q were performed as described in Materials and Methods. Viruses used for these assays were A/PR/8/34 (H1N1) and A/
Wuhan/359/95 (H3N2) that had been used to infect the cotton rats that were the source of this serum pool. Animals were boosted several times 
by rechallenging them with the same virus before serum was collected. The lowest dilution of serum used in the HAI assay was 1/10 and therefore 
no inhibition of agglutination is recorded as a titer of < 10. The lowest dilution of serum used in the neutralization assay was 1/100 and therefore no 
neutralization is recorded as a titer of < 100.Virology Journal 2008, 5:44 http://www.virologyj.com/content/5/1/44
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induce heterosubtypic immunity by comparing protec-
tion in animals that have been vaccinated i.n. and intra-
muscularly (i.m.). Since protection against tachypnea was
successfully transferred in serum from animals that were
immune to heterosubtypic virus, we expected that transu-
dated rather than local mucosal antibodies were responsi-
ble for this protection. The A/PR/8/34 virus was
inactivated by exposure to UV-light and its inability to
replicate verified by titration in MDCK cells. Equivalent
amounts of virus (107 TCID50/100 g) were used to inocu-
late groups of animals (4 animals per group) i.n. and i.m.
with live or inactivated virus. Serum samples were
obtained from all animals 2 weeks after immunization to
evaluate immune responses by measuring HAI titers.
As expected, exposure to live virus administered i.n.
resulted in greater HAI titers than exposure to inactivated
virus. Groups of cotton rats that were immunized with the
inactivated H1N1 virus were therefore boosted 3 times
with this virus preparation at 3 week intervals. At the time
of intranasal virus challenge with the heterosubtypic A/
Wuhan/95 virus, there was no inhibition of A/Wuhan/95
agglutination of chicken red blood cells. The serum HAI
geometric mean titers (GMT) against A/PR/8/34 varied
substantially in each of the groups (4 animals per group):
11 following i.n. immunization with inactivated virus; 28
following i.m. immunization with inactivated virus; 100
following i.n. inoculation with live virus; 82 following
i.m. inoculation with live virus. The HAI titer in sera of
cotton rats infected once with A/Wuhan/95 that served as
a homotypic control group, was 57. As expected, this
serum did not inhibit agglutination with the H1N1 virus.
Protection from influenza-induced tachypnea was
observed in the groups of animals immunized i.m. with
either live or inactivated virus preparations (Fig. 4), indi-
cating that a local immune response was not required to
provide cross-protection. Protection against tachypnea
was not observed in the group of animals immunized
intranasally with inactivated virus. This group had the
lowest HAI titer, suggesting that insufficient titers of cross-
protective antibodies had been attained under these con-
ditions.
Intramuscular immunization with inactivated H1N1 virus  protects against H3N2-induced tachypnea Figure 4
Intramuscular immunization with inactivated H1N1 
virus protects against H3N2-induced tachypnea. 
Groups of animals (4 cotton rats per group) were inoculated 
with the equivalent of 107 TCID50 A/PR/8/34 (H1N1) per 100 
g. Both live and UV-inactivated virus preparations were inoc-
ulated intranasally (i.n.) or intramuscularly (i.m.). Animals in 
groups immunized with inactivated virus were boosted at 
week 3 and 6. HAI titers of serum samples obtained by 
retro-orbital bleed 2 weeks following the final immunization 
are included in the text. All groups were challenged 10 
weeks following the first immunization with A/Wuhan/95 
(H3N2). Control groups included naïve animals that provided 
baseline RR, naïve animals infected with A/Wuhan/95 for the 
first time, and A/Wuhan/95-challenged H3N2-immune cot-
ton rats. RR were measured by whole body plethysmography 
and the percent protection from tachypnea calculated for 
each animal. Protection that was statistically greater than 
non-immune animals (p < 0.05) is marked with an *.
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Antibodies specific for M2 but not NP protect against influ- enza-induced tachypnea Figure 3
Antibodies specific for M2 but not NP protect against 
influenza-induced tachypnea. Groups of 6 animals were 
inoculated i.p. with 100 μg monoclonal antibody (anti-M2 or 
anti-NP) prepared in saline solution 24 hr before infection 
with A/Wuhan/95 (H3N2). Control groups of animals under-
went passive transfer of 0.5 ml (i.p.) of serum from H1N1-
immune animals, or were either infected with the same 
H3N2 virus or A/PR/8/34 (H1N1) virus 28 days earlier. The 
percent protection was calculated from RR measured by 
whole body plethysmography. Groups of animals that had RR 
statistically different (p < 0.05) from animals undergoing pri-
mary influenza infection are designated in the figure with an *.
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Discussion
Heterosubtypic immunity in man has been suggested
from epidemiologic studies of human outbreaks of influ-
enza A [4,5,16]. Identification of the immune compo-
nents necessary for a heterosubtypic immune response
will be critical in the development of more broadly pro-
tective vaccines effective against influenza A virus. Both
antibodies and cytotoxic T cells have been implicated in
cross-protective immune responses in murine models of
influenza infection, where the most often used end-point
is mortality.
In the cotton rat model, we previously demonstrated that
respiratory rate can be used as a measure of disease sever-
ity [13]. Protection from tachypnea is observed in cotton
rats immunized with one subtype of influenza A virus and
subsequently challenged with another subtype, demon-
strating a heterosubtypic immune response. This protec-
tion persists despite inhibition of the recruited memory
response [14]. The studies presented in this report show
that protection is mediated by humoral immunity since
passive transfer of immune serum from H1N1-immune
animals is able to transfer components necessary for pro-
tection from H3N2-induced tachypnea. Protection corre-
lates with HAI titer. While the HAI titer is a measure of a
subtype-specific antibodies, it also reflects the total
amount of antibody successfully administered during the
passive transfer and is therefore likely to correlate with the
amount of cross-reactive antibodies present in the serum.
These antibodies are most likely specific for conserved
epitopes of influenza A, and may include antibodies with
specificity for NP, M2e or conserved HA peptides. Non-
neutralizing HA-specific antibodies that may contribute
to B cell-dependent, heterosubtypic protection against
lethal infection by avian H5N1 influenza have been meas-
ured in the convalescent sera of mice [9]. While there is
good evidence that M2-specific antibodies are induced
following infection [17], we were unable to measure anti-
M2 titers in our cotton rat serum samples in an ELISA
using M2e peptide to coat the plates. The poor sensitivity
of this type of assay has been reported and it is known that
functional M2e-specific antibodies are best detected using
a cell-based expression system [17]. While we do not
know the fine specificities of antibodies present in conva-
lescent cotton rat sera, our results show that M2e-specific
but not NP-specific monoclonal antibodies can contrib-
ute to protection from influenza virus-induced tachypnea.
Further studies are needed to evaluate how antibodies
contribute to cross-protection. They may reduce the
amount of virus that can attach to cells by directing FcR-
positive macrophages to the pathogen for uptake and deg-
radation. A role for macrophages in heterosubtypic
immunity is supported by the studies of Sambhara et al.
[18]. Alternatively, cross-protective antibodies may work
in conjunction with NK cells as demonstrated for protec-
tion of mice by M2-specific antibodies [19]. Our finding
of antibody-mediated cross-protection against tachypnea
in the cotton rat model is an important step toward recog-
nition that this type of response is not limited to mice,
and is therefore likely to be present in other animal spe-
cies, including man.
Our results show that heterosubtypic immunity can be
induced by vaccination with either live or inactivated
virus that is administered intramuscularly. These results
differ from those reported by Tumpey et al. [8] and
Takada et al. [20] that show heterosubtypic protection in
mice following vaccination with intranasal but not intra-
muscular-delivery of an inactivated virus vaccine. This lat-
ter failure to protect against challenge in mice is likely to
reflect the relatively weak responses induced following
parental immunization. In our studies three intra-muscu-
lar administrations of inactivated virus resulted in HAI tit-
ers similar to those obtained following infection; this
vaccination regimen was sufficient for heterosubtypic pro-
tection supporting the idea that a mucosal IgA response is
not necessary for this protection.
Increased respiratory rate is a single facet of influenza dis-
ease, and while an antibody-mediated mechanism pro-
tects against virus-induced tachypnea in cotton rats, it is
likely that other immune mechanisms contribute to pro-
tection against other signs of disease. This may include
cytokines that have antiviral activity or activate macro-
phages, and cytotoxic T lymphocytes that play a role in
eradicating infected cells. Influenza vaccines that induce a
broad range of mechanisms are likely to offer the most
effective protection against all influenza A viruses, an
important consideration in the development of vaccines
designed to induce immunity against highly virulent
H5N1 strains with potential for pandemic spread. Our
results support the idea that antibodies specific for con-
served epitopes play a role in protection from influenza
induced disease and are therefore likely to contribute to
vaccine efficacy, particularly when HA and NA compo-
nents are poorly matched with circulating influenza A
viruses.
Conclusion
Passive transfer of serum from H1N1-immune cotton rats
provides protection against H3N2-induced tachypnea
even though the antiserum lacked subtype cross-reactivity
in standard HAI, NI or neutralization assays. Since recent
studies demonstrate that antibodies contribute to hetero-
subtypic immunity in mice, these studies in a second ani-
mal model support the idea that this mechanism may
provide some immune protection against respiratory dis-
ease in humans. Such heterosubtypic protection was
observed in animals immunized with either live or inacti-Virology Journal 2008, 5:44 http://www.virologyj.com/content/5/1/44
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vated virus preparations delivered intranasally or intra-
muscularly respectively, demonstrating that current
human influenza vaccine strategies are likely to induce
some heterosubtypic immunity. While the specificity of
antibodies that provide cross-protection is have not been
fully characterized, our results demonstrate that mono-
clonal antibodies to M2e but not NP provide some protec-
tion against virus-induced tachypnea. This supports the
idea that antibodies to conserved epitopes on the surface
of the virion or infected cell contribute to heterosubtypic
immunity. It is important to establish that similar
responses are induced following human vaccination and
contribute to vaccine efficacy. Our future studies will
therefore characterize the quality and quantity of antibod-
ies that provide heterosubtypic immunity so that tests can
be designed to evaluate these responses following human
vaccination.
Materials and methods
Cotton rats
Male and female inbred Sigmodon hispidus were obtained
from a breeding colony maintained at Virion Systems,
Inc., Rockville, MD. Animals were seronegative for adven-
titious viruses. Prior to infection, they were also seronega-
tive for influenza A as tested by HAI assay. Animals were
used at 6–12 weeks of age in protocols that follow federal
regulations and were approved by the Institutional Ani-
mal Care and Use Committee. Animals were sacrificed by
CO2 asphyxiation for the collection of tissue samples.
Viruses
Influenza A/Wuhan/359/95 (A/Wuhan/95), an H3N2
virus, was grown in MDCK cells at Novavax Inc. (Rock-
ville, MD), resulting in a virus stock solution of 108
TCID50/ml. Tissue culture-adapted influenza A/PR/8/34
(H1N1) was obtained from ATCC, and was grown in a
monolayer of MDCK cells resulting in a viral titer of 108
TCID50/ml. Virus was stored at -70°C, and thawed imme-
diately prior to use. Aliquots of A/PR/8/34 that were
exposed to UV-light did not contain any infectious virus.
Measurement of respiratory rates
Respiratory rates (RR) were measured by unrestrained
whole body flow plethysmography (Buxco Electronics
Inc., Wilmington, NC) as described previously [13]. After
calibration of the 2-chamber apparatus (designed to hold
adult rats), one cotton rat was placed in each chamber and
airway measurements were continuously recorded over a
5-minute period. The mean respiratory rate over the entire
5-minute period was calculated. Data from each group are
presented as mean breaths per minute (+/- standard error)
or as the percent protection from tachypnea calculated as:
100 - {100 × [(RRexperimental group - RRuninfected)/(RRprimary
infection-RRuninfected)]}.
Hemagglutination inhibition (HAI) assay
Serum was treated with receptor destroying enzyme
(RDE) overnight and then serially diluted in PBS. One
volume (25 μl) of each dilution was mixed with 1 volume
of A/Wuhan/95 containing 4 hemagglutinating units of
virus in a U-bottomed 96-well plate. After 30 min incuba-
tion at room temperature, 2 volumes of a 0.5% suspen-
sion of chicken red blood cells (CBT Farms, Chestertown,
MD) were added, the suspension gently mixed and left to
settle at room temperature for 30 min. Agglutination was
read and the inverse of the last dilution that inhibited
agglutination assigned as the titer.
Neuraminidase inhibition (NI) assay
Two-fold dilutions of serum (50 ul per well) were mixed
with an equal volume of virus. The amount of virus added
provided a signal 10-fold greater than background. Sub-
strate labeled with fluorochrome, 2,4-methylumbellifer-
one-N-acetyl neuraminic acid (MU-NANA), was then
added (100 μl of a 20 μM solution) as previously
described for measurement of NA activity [21]. After 1 hr
incubation at room temperature the reaction was stopped
by addition of 100 ul 0.1 M glycine, pH 10.7 containing
25% EtOH. Fluorescence (365 excitation, 460 emission,
0.1 sec per well) was read on a Victor 3 (Perkin Elmer).
The inverse of the last dilution of virus that resulted in at
least 50% reduction of NA activity was recorded as the NI
titer.
Virus neutralization assay
Serial dilutions of serum were made in DMEM, starting
with a 1/100 dilution. An equal volume (100 μl) of virus
(200 TCID50/ml) was added and the mixture incubated at
room temperature for 15 minutes. A portion (100 μl) of
the virus-antibody mixture was transferred to duplicate
MDCK cell monolayers in 96 well plates that had been
washed 3 times with serum-free medium. After 1 hr incu-
bation at 37°C, an equal volume of DMEM containing
1% bovine serum albumin and TPCK-treated trypsin (5
μg/ml) was added to each well, and the plates were
returned to the incubator. On day 3 of incubation, the
supernatants were discarded and the monolayers fixed
and stained with crystal violet. Neutralization titers were
assigned as the inverse of the last dilution that inhibited
the viral cytopathic effect in both of the duplicate wells.
The neutralization assay was also performed in the pres-
ence of complement, with addition of 25 μl of a solution
of C1q (5 μg/ml) to each well of the tissue culture plate.
Experimental design
Anesthetized animals were immunized by intranasal
(i.n.) administration of 107 TCID50 virus per 100 grams of
animal as previously described [22]. This dose of virus is
not lethal to cotton rats and corresponds to approximately
100 μl total volume (a 6 week old animal weighs approx-Virology Journal 2008, 5:44 http://www.virologyj.com/content/5/1/44
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imately 100 g). This volume is sufficient to deliver the
inoculum into the lower respiratory tract, resulting in
virus replication in lungs, trachea and nasal tissue. Groups
of animals that were not immunized, or immunized with
either A/Wuhan/95 (H3N2) or A/PR/8/34 (H1N1) were
challenged with the H3N2 virus four weeks later. Sera for
transfer studies were obtained from animals never
exposed to influenza (naïve control), or exposed to either
H3N2 or H1N1 viruses at 3-week intervals 3 times previ-
ously. The serum from individual animals in each group
were pooled and transferred (0.5 ml per animal) by intra-
peritoneal injection 24 hr prior to i.n. challenge with
virus. Twelve hr before challenge, retro-orbital bleeds
were performed on the recipient animals to obtain sera to
measure HAI titers. Respiratory rates were measured by
whole body plethysmography.
Statistical Analysis
Mean respiratory rates (RR) were compared between
groups by non-parametric Kruskal-Wallis and Mann-
Whitney tests. All analyses were performed using SPSS
(version 13.0) statistical software. P-values of <0.05 were
considered statistically significant.
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